Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
60
LZAGY Quote, Financials, Valuation and Earnings
Last price:
$67.91
Seasonality move
:
6.96%
Day range:
$67.39 - $67.96
52-week range:
$55.57 - $73.85
Dividend yield:
0.35%
P/E ratio:
57.26x
P/S ratio:
5.95x
P/B ratio:
4.40x
Volume:
46.3K
Avg. volume:
81.9K
1-year change:
14.73%
Market cap:
$47.4B
Revenue:
$7.5B
EPS (TTM):
$1.20
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LZAGY
Lonza Group AG
|
-- | -- | -- | -- | -- |
|
ACIU
AC Immune SA
|
$994.8K | -$0.22 | 18.17% | -6.14% | $9.61 |
|
ADXN
Addex Therapeutics Ltd.
|
$242.8K | -- | 2.35% | -- | $30.00 |
|
ALC
Alcon AG
|
$2.6B | $0.77 | 8.47% | 39.48% | $94.15 |
|
CRSP
CRISPR Therapeutics AG
|
$9M | -$1.29 | -89.16% | -180.62% | $81.33 |
|
ONC
BeOne Medicines Ltd.
|
$1.4B | $0.86 | 30.35% | -70.04% | $401.52 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LZAGY
Lonza Group AG
|
$67.52 | -- | $47.4B | 57.26x | $0.42 | 0.35% | 5.95x |
|
ACIU
AC Immune SA
|
$2.80 | $9.61 | $281.7M | -- | $0.00 | 0% | 54.60x |
|
ADXN
Addex Therapeutics Ltd.
|
$7.77 | $30.00 | $9.6M | 0.77x | $0.00 | 0% | 35.54x |
|
ALC
Alcon AG
|
$80.73 | $94.15 | $39.7B | 38.36x | $0.34 | 0.42% | 3.94x |
|
CRSP
CRISPR Therapeutics AG
|
$56.88 | $81.33 | $5.4B | -- | $0.00 | 0% | 129.74x |
|
ONC
BeOne Medicines Ltd.
|
$322.90 | $401.52 | $35.7B | 621.32x | $0.00 | 0% | 7.21x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LZAGY
Lonza Group AG
|
34.86% | -0.047 | -- | 0.87x |
|
ACIU
AC Immune SA
|
6.95% | 3.999 | 2.01% | 1.10x |
|
ADXN
Addex Therapeutics Ltd.
|
0.61% | 2.172 | 0.5% | 1.91x |
|
ALC
Alcon AG
|
19.18% | -0.654 | 14.32% | 1.14x |
|
CRSP
CRISPR Therapeutics AG
|
9.92% | 3.188 | 3.47% | 16.13x |
|
ONC
BeOne Medicines Ltd.
|
31.57% | 0.334 | 5.05% | 2.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LZAGY
Lonza Group AG
|
-- | -- | 5.53% | 8.18% | -- | -- |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
ADXN
Addex Therapeutics Ltd.
|
-- | -$869.9K | -73.49% | -73.84% | -1403.07% | -$687.4K |
|
ALC
Alcon AG
|
$1.5B | $347M | 3.87% | 4.8% | 13.28% | $535M |
|
CRSP
CRISPR Therapeutics AG
|
-$60.6M | -$132.1M | -23.42% | -26.17% | -14854.78% | -$84.7M |
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
Lonza Group AG vs. Competitors
-
Which has Higher Returns LZAGY or ACIU?
AC Immune SA has a net margin of -- compared to Lonza Group AG's net margin of -1688.87%. Lonza Group AG's return on equity of 8.18% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital LZAGYLonza Group AG-- -- $16.6B ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About LZAGY or ACIU?
Lonza Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand AC Immune SA has an analysts' consensus of $9.61 which suggests that it could grow by 244.63%. Given that AC Immune SA has higher upside potential than Lonza Group AG, analysts believe AC Immune SA is more attractive than Lonza Group AG.
Company Buy Ratings Hold Ratings Sell Ratings LZAGYLonza Group AG0 0 0 ACIUAC Immune SA3 0 0 -
Is LZAGY or ACIU More Risky?
Lonza Group AG has a beta of 1.235, which suggesting that the stock is 23.547% more volatile than S&P 500. In comparison AC Immune SA has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.243%.
-
Which is a Better Dividend Stock LZAGY or ACIU?
Lonza Group AG has a quarterly dividend of $0.42 per share corresponding to a yield of 0.35%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lonza Group AG pays 29.42% of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend. Lonza Group AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LZAGY or ACIU?
Lonza Group AG quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $1.2M. Lonza Group AG's net income of -- is lower than AC Immune SA's net income of -$19.8M. Notably, Lonza Group AG's price-to-earnings ratio is 57.26x while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lonza Group AG is 5.95x versus 54.60x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LZAGYLonza Group AG5.95x 57.26x -- -- ACIUAC Immune SA54.60x -- $1.2M -$19.8M
-
Which has Higher Returns LZAGY or ADXN?
Addex Therapeutics Ltd. has a net margin of -- compared to Lonza Group AG's net margin of -3178.71%. Lonza Group AG's return on equity of 8.18% beat Addex Therapeutics Ltd.'s return on equity of -73.84%.
Company Gross Margin Earnings Per Share Invested Capital LZAGYLonza Group AG-- -- $16.6B ADXNAddex Therapeutics Ltd.-- -$2.10 $7.5M -
What do Analysts Say About LZAGY or ADXN?
Lonza Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Addex Therapeutics Ltd. has an analysts' consensus of $30.00 which suggests that it could grow by 286.1%. Given that Addex Therapeutics Ltd. has higher upside potential than Lonza Group AG, analysts believe Addex Therapeutics Ltd. is more attractive than Lonza Group AG.
Company Buy Ratings Hold Ratings Sell Ratings LZAGYLonza Group AG0 0 0 ADXNAddex Therapeutics Ltd.0 0 0 -
Is LZAGY or ADXN More Risky?
Lonza Group AG has a beta of 1.235, which suggesting that the stock is 23.547% more volatile than S&P 500. In comparison Addex Therapeutics Ltd. has a beta of 1.573, suggesting its more volatile than the S&P 500 by 57.32%.
-
Which is a Better Dividend Stock LZAGY or ADXN?
Lonza Group AG has a quarterly dividend of $0.42 per share corresponding to a yield of 0.35%. Addex Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lonza Group AG pays 29.42% of its earnings as a dividend. Addex Therapeutics Ltd. pays out -- of its earnings as a dividend. Lonza Group AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LZAGY or ADXN?
Lonza Group AG quarterly revenues are --, which are smaller than Addex Therapeutics Ltd. quarterly revenues of $62K. Lonza Group AG's net income of -- is lower than Addex Therapeutics Ltd.'s net income of -$2M. Notably, Lonza Group AG's price-to-earnings ratio is 57.26x while Addex Therapeutics Ltd.'s PE ratio is 0.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lonza Group AG is 5.95x versus 35.54x for Addex Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LZAGYLonza Group AG5.95x 57.26x -- -- ADXNAddex Therapeutics Ltd.35.54x 0.77x $62K -$2M
-
Which has Higher Returns LZAGY or ALC?
Alcon AG has a net margin of -- compared to Lonza Group AG's net margin of 9.07%. Lonza Group AG's return on equity of 8.18% beat Alcon AG's return on equity of 4.8%.
Company Gross Margin Earnings Per Share Invested Capital LZAGYLonza Group AG-- -- $16.6B ALCAlcon AG55.78% $0.48 $27.3B -
What do Analysts Say About LZAGY or ALC?
Lonza Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Alcon AG has an analysts' consensus of $94.15 which suggests that it could grow by 16.63%. Given that Alcon AG has higher upside potential than Lonza Group AG, analysts believe Alcon AG is more attractive than Lonza Group AG.
Company Buy Ratings Hold Ratings Sell Ratings LZAGYLonza Group AG0 0 0 ALCAlcon AG15 7 0 -
Is LZAGY or ALC More Risky?
Lonza Group AG has a beta of 1.235, which suggesting that the stock is 23.547% more volatile than S&P 500. In comparison Alcon AG has a beta of 0.967, suggesting its less volatile than the S&P 500 by 3.321%.
-
Which is a Better Dividend Stock LZAGY or ALC?
Lonza Group AG has a quarterly dividend of $0.42 per share corresponding to a yield of 0.35%. Alcon AG offers a yield of 0.42% to investors and pays a quarterly dividend of $0.34 per share. Lonza Group AG pays 29.42% of its earnings as a dividend. Alcon AG pays out 15.44% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LZAGY or ALC?
Lonza Group AG quarterly revenues are --, which are smaller than Alcon AG quarterly revenues of $2.6B. Lonza Group AG's net income of -- is lower than Alcon AG's net income of $237M. Notably, Lonza Group AG's price-to-earnings ratio is 57.26x while Alcon AG's PE ratio is 38.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lonza Group AG is 5.95x versus 3.94x for Alcon AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LZAGYLonza Group AG5.95x 57.26x -- -- ALCAlcon AG3.94x 38.36x $2.6B $237M
-
Which has Higher Returns LZAGY or CRSP?
CRISPR Therapeutics AG has a net margin of -- compared to Lonza Group AG's net margin of -11973.12%. Lonza Group AG's return on equity of 8.18% beat CRISPR Therapeutics AG's return on equity of -26.17%.
Company Gross Margin Earnings Per Share Invested Capital LZAGYLonza Group AG-- -- $16.6B CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B -
What do Analysts Say About LZAGY or CRSP?
Lonza Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.33 which suggests that it could grow by 42.99%. Given that CRISPR Therapeutics AG has higher upside potential than Lonza Group AG, analysts believe CRISPR Therapeutics AG is more attractive than Lonza Group AG.
Company Buy Ratings Hold Ratings Sell Ratings LZAGYLonza Group AG0 0 0 CRSPCRISPR Therapeutics AG12 10 1 -
Is LZAGY or CRSP More Risky?
Lonza Group AG has a beta of 1.235, which suggesting that the stock is 23.547% more volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.738, suggesting its more volatile than the S&P 500 by 73.75%.
-
Which is a Better Dividend Stock LZAGY or CRSP?
Lonza Group AG has a quarterly dividend of $0.42 per share corresponding to a yield of 0.35%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lonza Group AG pays 29.42% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend. Lonza Group AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LZAGY or CRSP?
Lonza Group AG quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of $889K. Lonza Group AG's net income of -- is lower than CRISPR Therapeutics AG's net income of -$106.4M. Notably, Lonza Group AG's price-to-earnings ratio is 57.26x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lonza Group AG is 5.95x versus 129.74x for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LZAGYLonza Group AG5.95x 57.26x -- -- CRSPCRISPR Therapeutics AG129.74x -- $889K -$106.4M
-
Which has Higher Returns LZAGY or ONC?
BeOne Medicines Ltd. has a net margin of -- compared to Lonza Group AG's net margin of 8.84%. Lonza Group AG's return on equity of 8.18% beat BeOne Medicines Ltd.'s return on equity of 1.92%.
Company Gross Margin Earnings Per Share Invested Capital LZAGYLonza Group AG-- -- $16.6B ONCBeOne Medicines Ltd.83.86% $1.09 $6B -
What do Analysts Say About LZAGY or ONC?
Lonza Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $401.52 which suggests that it could grow by 24.35%. Given that BeOne Medicines Ltd. has higher upside potential than Lonza Group AG, analysts believe BeOne Medicines Ltd. is more attractive than Lonza Group AG.
Company Buy Ratings Hold Ratings Sell Ratings LZAGYLonza Group AG0 0 0 ONCBeOne Medicines Ltd.18 1 1 -
Is LZAGY or ONC More Risky?
Lonza Group AG has a beta of 1.235, which suggesting that the stock is 23.547% more volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.452, suggesting its less volatile than the S&P 500 by 54.771%.
-
Which is a Better Dividend Stock LZAGY or ONC?
Lonza Group AG has a quarterly dividend of $0.42 per share corresponding to a yield of 0.35%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lonza Group AG pays 29.42% of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend. Lonza Group AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LZAGY or ONC?
Lonza Group AG quarterly revenues are --, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. Lonza Group AG's net income of -- is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, Lonza Group AG's price-to-earnings ratio is 57.26x while BeOne Medicines Ltd.'s PE ratio is 621.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lonza Group AG is 5.95x versus 7.21x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LZAGYLonza Group AG5.95x 57.26x -- -- ONCBeOne Medicines Ltd.7.21x 621.32x $1.4B $125M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 65.66% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 9.94% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 4.41% over the past day.
